Adjusted EBITDA in the fourth quarter was $330 million , up 27% , with an adjusted EBITDA margin of 23.5% , which Eldessouky said was the highest level the company has achieved as a standalone company since its IPO. Full-year adjusted EBITDA was $891 million , and adjusted EBITDA margin for the full year was 17.5% .CFO Sam Eldessouky reported total company revenue of $1.405 billion in the fourth quarter, up 7% on a constant-currency basis. Full-year revenue was $5.101 billion , up 5% , and up 6% excluding t ...

Bausch + Lomb (NYSE:BLCO) Q4 2025 Earnings call February 18, 2026 08:00 AM ET Company ParticipantsAndrew Stewart - President of Global Pharmaceuticals and International ConsumerBrent Saunders - Chairman and CEODavid Roman - Managing DirectorDouglas Miehm - Managing DirectorGeorge Gadkowski - VP of Investor Relations and Business InsightsJoanne Wuensch - Managing Director, Head of U.S. Healthcare ResearchPatrick Wood - Managing DirectorSam Eldessouky - CFOYehia Hashad - EVP and Chief Medical OfficerConferenc ...

Group 1: Retail Stocks Overview - Seven retail stocks to watch include Amazon.com, American Noble Gas, Costco Wholesale, Carvana, Walmart, Home Depot, and PDD, as identified by MarketBeat's stock screener tool [2] - Retail stocks are primarily traded by individual investors, leading to significant short-term price fluctuations compared to stocks dominated by institutional investors [2] Group 2: Company Profiles - **Amazon.com (AMZN)**: Engages in retail sales of consumer products, advertising, and subscription services through online and physical stores, operating in three segments: North America, International, and Amazon Web Services (AWS) [3] - **American Noble Gas (INFY)**: Infosys Ltd. provides end-to-end business solutions across various sectors, including Financial Services, Retail, and Life Sciences [4] - **Costco Wholesale (COST)**: Operates membership warehouses globally, offering a range of branded and private-label products [4] - **Carvana (CVNA)**: Operates an e-commerce platform for buying and selling used cars, providing services such as vehicle inspection and financing [5] - **Walmart (WMT)**: Engages in retail and wholesale operations worldwide, with segments including Walmart U.S., Walmart International, and Sam's Club [6] - **Home Depot (HD)**: Functions as a home improvement retailer, selling building materials and offering installation services for various home products [7] - **PDD (PDD)**: Operates Pinduoduo and Temu, e-commerce platforms offering a wide range of products, including agricultural produce and household goods [8]

Financial Data and Key Metrics Changes - The company is focused on achieving financial excellence, particularly improving EBITDA margins to align with or exceed competitors [4][5] - A three-year plan was announced, targeting a revenue growth rate of 5%-7% and a consistent margin improvement of approximately 200 basis points per year [12][56] Business Line Data and Key Metrics Changes - The Vision 27 program aims to enhance operational excellence and gross margins, with thousands of employees involved in various projects [5][7] - The contact lens market is experiencing a slowdown, with growth around 4%, but the company is growing faster than the market [23][24] Market Data and Key Metrics Changes - The company noted a slowdown in the Asian markets, particularly in China, which is affecting overall growth [23][24] - The bifurcation in consumer spending is evident, with lower-end consumers feeling more financial pressure compared to middle and high-income consumers [24] Company Strategy and Development Direction - The company is prioritizing organic growth over M&A, with a focus on enhancing its existing pipeline and improving its balance sheet [15][16] - Innovation is a key focus, with new products like Project Halo aimed at addressing significant consumer issues in the contact lens market [18][19] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to achieve its targets, citing recent sales growth and margin improvements as indicators of progress [10][56] - The company is optimistic about the future, expecting to see continued growth and innovation leading to a stronger market position [5][10] Other Important Information - The company is committed to improving its liquidity and addressing its ownership structure, which is currently 88% owned by Bausch Health [11] - The pipeline is projected to generate over $7 billion in potential revenue, highlighting significant growth opportunities [54] Q&A Session Summary Question: What components contributed to the 5%-7% revenue long-range plan? - Management acknowledged the difficulty in predicting future performance but expressed confidence in their balanced guidance based on current market conditions [12][13] Question: How does the company view tuck-in M&A? - The company currently does not require M&A for its three-year plan, focusing instead on organic growth and improving its balance sheet [15][16] Question: What is the expected timeline for new product launches? - The company anticipates launching new products, including a bioactive contact lens, by 2028, with clinical studies ongoing [19][22] Question: How is the company managing its R&D budget? - The company is increasing its R&D budget to approximately 7.5% of revenue, focusing on programs that promise the best returns [36][38] Question: What is the outlook for the dry eye market? - Management believes they have the best portfolio for treating dry eye, with Xiidra and Miebo positioned as leading products in the market [40][41]

Financial Data and Key Metrics Changes - The company is focused on achieving financial excellence, particularly improving EBITDA margins to align with or exceed competitors [5][6][11] - A three-year plan was announced, targeting a revenue growth rate of 5%-7% [13][15] - The company aims for a net leverage of 3.5 times by 2028 [18] Business Line Data and Key Metrics Changes - The Vision 27 program is designed to enhance operational efficiency and gross margins across various business lines [6][11] - The contact lens segment is expected to grow faster than the market, with a new bioactive platform, Project Halo, set to launch in 2028 [21][27] - The dry eye product portfolio, including Xiidra and Miebo, is positioned as the gold standard in the market [52] Market Data and Key Metrics Changes - The contact lens market has slowed to about 4% growth, influenced by economic conditions in Asia, particularly China [28][29] - The company anticipates a recovery in the contact lens market, projecting growth to return to 5% or higher by 2026 [29] Company Strategy and Development Direction - The company is committed to organic growth, with no M&A planned in the three-year strategy [18] - Focus on innovation is critical, with a deep pipeline of products expected to drive future growth [90] - The company aims to leverage its existing infrastructure for new product launches to maintain high margins [27] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's transformation into a high-performance competitor, emphasizing the importance of innovation and operational excellence [5][6] - The management highlighted the need for a disciplined approach to spending as growth resumes [9][11] - The company is optimistic about the aging population's demand for premium IOLs, viewing it as a growth driver [89] Other Important Information - The company is focusing on enhancing its R&D efficiency, aiming to allocate more resources towards product development rather than administrative costs [50] - The introduction of new products like Lumify Luxe and the expansion of the PreserVision brand are seen as significant growth opportunities [44][46] Q&A Session Summary Question: How should investors think about the liquidity of Bausch + Lomb given its ownership structure? - Management acknowledged the 88% ownership by Bausch Health and indicated that both boards are committed to addressing liquidity issues, though the timeline is uncertain [12] Question: What are the components of the 5%-7% revenue long-range plan? - Management explained that the guidance is based on current market conditions and internal capabilities, with a balanced approach to growth [13][15] Question: How does the company view tuck-in M&A opportunities? - Management stated that no M&A is needed at this time, focusing instead on organic growth and improving the balance sheet [18] Question: What is the expected timeline for the new bioactive contact lens material? - The new product is expected to launch in 2028, with ongoing clinical studies providing positive data [24][27] Question: How does the company plan to manage its R&D budget? - The company is increasing its R&D spending to about 7.5% of revenue, focusing on high-potential programs [48][50] Question: What is the outlook for the dry eye market? - Management believes they have the best portfolio for dry eye treatment, with Xiidra and Miebo positioned as leading products [52] Question: What is the growth outlook for the surgical business? - The surgical business is expected to grow steadily, driven by an aging population and consistent demand for IOLs [89]

Financial Data and Key Metrics Changes - Total company revenue for Q3 2025 was $1.281 billion, reflecting a year-over-year growth of 6% [10][11] - Adjusted EBITDA for Q3 was $243 million, up 7% year-over-year, with an adjusted EBITDA margin of 19%, representing a sequential increase of 400 basis points [14][15] - Adjusted cash flow from operations was $161 million, with adjusted free cash flow at $87 million, indicating strong cash flow generation [14][15] Business Line Data and Key Metrics Changes - Vision Care revenue for Q3 was $736 million, increasing by 6%, driven by growth in both consumer and contact lenses [10][11] - Pharmaceuticals segment revenue was $330 million, representing a 7% increase, with MIEBO contributing $84 million, showing a 71% year-over-year increase [13][14] - Surgical segment revenue was $215 million, a 1% increase, with a 7% growth excluding the enVista recall [12][14] Market Data and Key Metrics Changes - The U.S. branded RX business in pharmaceuticals grew by 13%, while the international pharmaceuticals business was up 12% [13][14] - The contact lens market is growing at a low end of the mid-single digit range, with the company outpacing market growth [38][80] - The company reported a 9% growth in the U.S. contact lens market and a 4% growth internationally [12][11] Company Strategy and Development Direction - The company is focused on three core pillars: Selling Excellence, Operational Excellence, and Disruptive Innovation, with the addition of a fourth pillar, Financial Excellence, aimed at improving cash conversion and margin structure [6][27] - The company plans to showcase its pipeline of innovative products at the upcoming Investor Day, emphasizing sustained, profitable growth [7][10] - The strategy includes maintaining a strong field force and focusing on combination therapies to expand the dry eye market [105] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the ongoing growth of the dry eye market, with MIEBO and Xiidra expected to benefit from increased awareness and education [18][104] - The company is monitoring tariff impacts closely, with expectations to offset potential tariff costs in 2025 [16][78] - Management highlighted the importance of disciplined execution and resource allocation to drive financial excellence and margin expansion [27][29] Other Important Information - The company maintained its full-year revenue guidance at $5.05 billion to $5.15 billion, representing constant currency growth of approximately 5%-7% [15][16] - Adjusted gross margin for Q3 was 61.7%, reflecting a 130 basis points decrease year-over-year due to product mix and the enVista recall [14][88] Q&A Session Summary Question: Commentary on Financial Excellence pillar - Management explained that Financial Excellence focuses on ensuring every dollar spent drives growth and efficiency, emphasizing disciplined execution and better resource allocation [26][27] Question: Insights on contact lens market share - Management noted that the contact lens market is growing in the mid-single digits, with the company growing faster than the market due to new product innovations [38][39] Question: MIEBO and combination therapies - Management discussed the potential for combination therapies to expand the dry eye market, highlighting MIEBO's unique position in treating evaporative dry eye [44][51] Question: Surgical business recovery post-recall - Management reported strong recovery in the enVista IOL platform, with sales approaching pre-recall levels and a focus on regaining market trust [58][60] Question: Sustainability of SG&A leverage - Management indicated that the recent SG&A improvements are sustainable, with a focus on reallocating resources towards revenue generation [66][68] Question: Tariff impact and market growth outlook - Management acknowledged the fluidity of the tariff situation but expressed confidence in the ability to manage and offset impacts, while also noting mixed signals in market growth [78][80]

Financial Data and Key Metrics Changes - Total company revenue for Q3 2025 was $1.281 billion, reflecting year-over-year growth of 6% [10] - Adjusted EBITDA for Q3 was $243 million, up 7% year-over-year, with an adjusted EBITDA margin of 19%, representing a sequential increase of 400 basis points [14][15] - Adjusted cash flow from operations was $161 million, with adjusted free cash flow at $87 million, indicating strong cash flow generation [14] Business Line Data and Key Metrics Changes - Vision Care revenue for Q3 was $736 million, increasing by 6%, driven by growth in both consumer and contact lenses [10] - Pharmaceuticals segment revenue was $330 million, representing a 7% increase, with MIEBO generating $84 million, a 71% year-over-year increase [13] - Surgical segment revenue was $215 million, a 1% increase, with premium IOLs showing 27% constant currency revenue growth [12][13] Market Data and Key Metrics Changes - The U.S. branded RX business in pharmaceuticals grew by 13%, while the international pharmaceuticals business was up 12% [13] - The contact lens market is growing at a mid-single-digit rate, with the company outpacing the market growth [41][80] - The company reported a 9% growth in the U.S. contact lens market and a 4% growth internationally [12] Company Strategy and Development Direction - The company is focused on four strategic pillars: Selling Excellence, Operational Excellence, Disruptive Innovation, and Financial Excellence [5][6] - The upcoming Investor Day will showcase a three-year plan aimed at delivering sustained, profitable growth [6][15] - The company aims to elevate the standard of care in eye health through innovative product launches and a strong pipeline [6][7] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the growth potential of the dry eye market, anticipating continued expansion due to increased awareness and education [18][100] - The company is committed to maintaining a disciplined approach to cost management while investing in R&D for future growth [15][66] - Management noted that the tariff situation remains fluid but expressed confidence in the ability to mitigate impacts [75][78] Other Important Information - Adjusted gross margin for Q3 was 61.7%, a decrease of 130 basis points year-over-year, primarily due to product mix and the Invista IOL recall [14][86] - The company is maintaining its full-year revenue guidance at $5.05 billion to $5.15 billion, representing constant currency growth of approximately 5% to 7% [15][16] Q&A Session Summary Question: Commentary on Financial Excellence pillar - Management explained that the Financial Excellence pillar focuses on ensuring every dollar spent drives growth and efficiency, emphasizing disciplined execution and resource allocation [24][26] Question: Insights on contact lens market share - Management indicated that the contact lens market is growing in the mid-single digits, with the company growing faster than the market due to new product innovations [41][42] Question: MIEBO's performance and market opportunity - Management highlighted MIEBO's strong TRx growth of 110% year-over-year, indicating a positive outlook for the dry eye treatment market [18][49] Question: Surgical business and Invista IOL recovery - Management reported impressive recovery in the Invista IOL platform, with sales reaching 82% of pre-recall levels, and expressed confidence in regaining market momentum [58][60] Question: Capital allocation strategy - Management confirmed a commitment to deleveraging while also considering reinvestment in R&D and potential M&A opportunities [108]

Product Development - Amazon 通过 Ring 和 Blink 品牌推出了一系列新的安全摄像头，作为更大规模的硬件改革的一部分 [1]

Core Insights - Amazon has a significant market capitalization of $2.45 trillion and generates approximately $650 billion in annual revenue, with a net profit margin of around 10% [8][9] - The company employs about 1,556,000 full-time and part-time employees, making it the world's second-largest employer [7] - Amazon's brand value is estimated at $356 billion, ranking it as the fourth-most valuable brand globally [11] Company Background - Amazon was originally named Cadabra before being rebranded to its current name, which reflects its wide range of products from A to Z [4] - The company has evolved from a simple online retailer to a major player in various sectors, including cloud computing with Amazon Web Services (AWS) [12][13] Financial Performance - Since its IPO in May 1997, Amazon has experienced an average annual growth rate of 32%, turning an initial investment of $10,000 into nearly $26 million [9] - The company derives 59% of its revenue from services, indicating a strong presence in the cloud computing market [12] Business Diversification - Amazon operates multiple businesses and brands, including Whole Foods Market, Zappos.com, and Twitch, and offers various services under the Amazon Prime umbrella [12][13] - The company has also ventured into healthcare and robotics, indicating a strategy of diversification and innovation [13]

Core Insights - FARO Technologies, Inc. reported strong first-quarter financial results for 2025, exceeding expectations and reflecting successful execution of strategic growth initiatives [2] - The company achieved a 6% year-over-year growth in net orders, driven by refreshed products and new solutions [2] - FARO's GAAP net income was $0.9 million, with adjusted EBITDA of $12.5 million, representing 15.0% of revenue, surpassing forecasts [2] Financial Performance - Total revenue for Q1 2025 was $82.9 million, slightly down 1.6% year-over-year [7] - Gross margin improved to 57.0%, compared to 51.4% in the prior year, while non-GAAP gross margin was 57.7% [7][6] - Operating expenses decreased to $43.4 million from $48.6 million in the prior year [7] - Net income per share was $0.05, a significant recovery from a net loss of $0.38 per share in the prior year [7] Operational Highlights - The company launched new products, including the Leap ST and Blink, which are expected to expand its market opportunities [2] - Cash flow from operations was reported at $5.0 million, indicating strong operational efficiency [6] - FARO's total cash, cash equivalents, and short-term investments increased to $102.6 million from $98.7 million at the end of 2024 [7] Outlook - For Q2 2025, FARO expects revenue in the range of $79 to $87 million, with gross margin between 56.5% and 58.0% [8] - The company anticipates non-GAAP net income per share to range from $0.20 to $0.40 [8]